Sign in4 stories
The moves are meant to expand AI use across ProQR's Axiomer RNA editing programs, with an early readout for lead AI-discovered candidate AX-0811 expected in January 2027.
SEC filing
The clinical-stage RNA editing company also set a September 30, 2026 investor event to discuss NTCP modulation in biliary atresia.
SEC filing
The July 15, 2026 filing covers shares issued in an April 2026 private placement, with expenses borne by ProQR except for the selling shareholder's own counsel and trading costs.
SEC filing